`
`UNITED STATES DISTRICT COURT
`SOUTHERN DISTRICT OF NEW YORK
`
`
`ACUITAS THERAPEUTICS INC.,
`
`Plaintiff,
`
`Case No. 1:22-cv-02229-MKV
`
`vs.
`
`GENEVANT SCIENCES GMBH, and
`ARBUTUS BIOPHARMA CORP.,
`
`Defendants.
`
`
`
`
`
`
`
`
`
`
`
`NOTICE OF DEFENDANT ARBUTUS BIOPHARMA CORP.’S MOTION TO DISMISS
`THE FIRST AMENDED COMPLAINT PURSUANT TO FEDERAL RULE OF CIVIL
`PROCEDURE 12(b)(1)
`
`PLEASE TAKE NOTICE that, upon the Notice of Motion of Defendant Genevant Sciences
`
`GmbH to Dismiss the First Amended Complaint Pursuant to Federal Rule of Civil Procedure
`
`12(b)(1), dated October 4, 2022; the Memorandum of Law in Support of Defendants’ Motion to
`
`Dismiss Pursuant to Federal Rule of Civil Procedure 12(b)(1), dated October 4, 2022; the
`
`Declaration of Matthew D. Robson, dated October 4, 2022, and exhibits thereto; and upon all the
`
`papers and proceedings had herein, Defendant Arbutus Biopharma Corp. (“Arbutus”) will move
`
`this Court, before the Honorable Mary Kay Vyskocil, United States District Judge, at the Daniel
`
`Patrick Moynihan United States Courthouse, 500 Pearl Street, New York, New York 10007, on a
`
`date and at a time designated by the Court, for an Order pursuant to Federal Rule of Civil Procedure
`
`12(b)(1) dismissing the First Amended Complaint in its entirety with prejudice and granting such
`
`other and further relief as this Court may deem just and proper.
`
`
`
`1
`
`
`
`Case 1:22-cv-02229-MKV Document 46 Filed 10/04/22 Page 2 of 2
`
`Dated: October 4, 2022
`
` Los Angeles, California
`
`
`
`
`
`Respectfully submitted,
`
`By: /s/ Kira A. Davis
`Daralyn J. Durie (pro hac vice)
`Eric C. Wiener (pro hac vice)
`DURIE TANGRI LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`T: 415-362-6666
`
`Kira A. Davis
`DURIE TANGRI LLP
`953 East 3rd Street
`Los Angeles, CA 90013
`T: 213-992-4499
`
`Attorneys for Defendant Arbutus
`Biopharma Corp.
`
`
`
`2
`
`
`
`
`
`
`
`